Telix to Present at the 2021 Jefferies Virtual Healthcare Conference
01 juin 2021 08h00 HE
|
Telix Pharmaceuticals Limited
MELBOURNE, Australia and NEW YORK, June 01, 2021 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that Chief Executive Officer, Dr. Christian...
Telix Pharmaceuticals and Grand River Aseptic Manufacturing Complete Agreement for Commercial Manufacturing of Illuccix®
30 mars 2021 18h02 HE
|
Telix Pharmaceuticals Limited
MELBOURNE, Australia and INDIANAPOLIS, March 30, 2021 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, ‘Telix’, the ‘Company’) announces today that it has completed an agreement with...
Czech Republic First European Country to Grant National Authorisation for the Use of Telix’s Prostate Cancer Imaging Product
16 févr. 2021 01h05 HE
|
Telix Pharmaceuticals Limited
MELBOURNE, Australia and LIÈGE, Belgium, Feb. 16, 2021 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, ‘Telix’, the ‘Company’) announces today that the Ministry of Health of the...
Telix Pharmaceuticals Submits New Drug Application to US FDA for Prostate Cancer Imaging Product
24 sept. 2020 07h00 HE
|
Telix Pharmaceuticals Limited
MELBOURNE, Australia and INDIANAPOLIS, Sept. 24, 2020 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, ‘Telix’, the ‘Company’) today announces it has submitted a New Drug Application...
Telix Pharmaceuticals Submits New Drug Application to US FDA for Prostate Cancer Imaging Product
23 sept. 2020 19h30 HE
|
Telix Pharmaceuticals Limited
MELBOURNE, Australia and INDIANAPOLIS, Sept. 24, 2020 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, ‘Telix’, the ‘Company’) today announces it has submitted a New Drug Application...
First Patient Dosed in Phase I/II Trial of Renal Cancer Imaging Product in Japan
17 août 2020 20h00 HE
|
Telix Pharmaceuticals Limited
TOKYO, Aug. 18, 2020 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Japan K.K., a wholly-owned subsidiary of Telix Pharmaceuticals Limited (ASX: TLX, ‘Telix’, the ‘Company’) is pleased to announce that...
Telix Japan Signs MOU with ATOX to Use IRE ELiT 68Ge/68Ga-Generator for Phase I Study of Prostate Cancer Diagnostic Imaging
27 juil. 2020 02h21 HE
|
Telix Pharmaceuticals Limited
TOKYO, July 27, 2020 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Japan K.K., a wholly-owned subsidiary of Telix Pharmaceuticals Limited (ASX: TLX, ‘Telix’, the ‘Company’) is pleased to announce it has...
Telix Pharmaceuticals submits European marketing authorisation application for prostate cancer imaging product
30 avr. 2020 20h14 HE
|
Telix Pharmaceuticals Limited
MELBOURNE, Australia and LIÈGE, Belgium, May 01, 2020 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, ‘Telix’, the ‘Company’) today announces that it has submitted a marketing...
Telix Pharmaceuticals to Present at Jefferies Healthcare Conference
03 juin 2019 08h54 HE
|
Telix Pharmaceuticals Limited
MELBOURNE, Australia and NEW YORK, June 03, 2019 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX.TLX) (“Telix”, the “Company”), a clinical-stage biopharmaceutical company focused on the...
Telix Pharmaceuticals and Emory Winship Cancer Institute to Collaborate on Clinical Trial Using Advanced Imaging of Prostate Cancer for Radiotherapy
30 mai 2019 09h00 HE
|
Telix Pharmaceuticals Limited
MELBOURNE, Australia and ATLANTA, May 30, 2019 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX.TLX) (“Telix”, the “Company”), a clinical-stage biopharmaceutical company focused on the...